# A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.

> **NCT02017899** · PHASE1 · COMPLETED · sponsor: **GSK Vaccines Institute For Global Health S.r.l.** · enrollment: 50 (actual)

## Conditions studied

- Shigellosis

## Interventions

- **BIOLOGICAL:** S. sonnei 1790GAHB
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02017899
- **Lead sponsor:** GSK Vaccines Institute For Global Health S.r.l.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2019-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02017899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02017899, "A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02017899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*